ERBB2 and neoplasm: The produced 131I-YZHER2: V2 demonstrates tumor accumulation, prolonged tumor retention, a high tumor-to-background ratio, favorable biodistribution and therapeutic efficacy in mice bearing HER2-positive tumors.